# A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

> **NCT06292780** · PHASE1,PHASE2 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 220 (estimated)

## Conditions studied

- Relapsed/Refractory Systemic Light Chain Amyloidosis

## Interventions

- **DRUG:** Linvoseltamab

## Key facts

- **NCT ID:** NCT06292780
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-07
- **Primary completion:** 2028-08-20
- **Final completion:** 2035-02-20
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06292780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06292780, "A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06292780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*